ArticleCancer biology & medicine2026
SARS-CoV-2 infection in brain tumors and the association with alterations in the tumor immune microenvironment.
Article in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveRecent clinical evidence indicates that persistent reservoirs of SARS-CoV-2 in human brain tissue are associated with various neurologic symptoms. While brain tumors have unique vascular abnormalities and immunosuppressive environments, it is unclear whether SARS-CoV-2 can infect brain tumors.
methodsBrain tumor samples were collected from a cohort of 72 COVID-19 patients during the SARS-CoV-2 BA.5 wave in Guangzhou. SARS-CoV-2 infection was confirmed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and immunohistochemical (IHC) staining. Immune cell infiltration within the tumor tissues was assessed using IHC. RNA-sequencing was performed to investigate virus-host interactions in the brain tumors.
resultsBrain tumor samples from 72 COVID-19 patients were examined and SARS-CoV-2 RNA was detected in 11% of the samples, which included samples from craniopharyngiomas, pituitary neuroendocrine tumors (PitNETs), meningiomas, and gliomas. SARS-CoV-2 infection was present in tumor and endothelial cells within these brain tumors. SARS-CoV-2-positive tumors had greater immune cell infiltration, particularly an increase in CD8
conclusionsThese findings provided evidence of SARS-CoV-2 infection in brain tumors and suggested a role in altering the tumor immunosuppressive microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.